Join
Live feed
·
INSIDERFilingvia Quantisnow
Tarsus Pharmaceuticals Inc. logo

Director Goodrich Katherine sold $183,384 worth of shares (2,954 units at $62.08) as part of a pre-agreed trading plan, decreasing direct ownership by 57% to 2,233 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
TARS· Tarsus Pharmaceuticals Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TARS (Tarsus Pharmaceuticals Inc.) and more on Quantisnow.